MTOR and endometrial cancer: Patients with endometrial cancer harboring CTNNB1 mutations responded well to everolimus (NCT01068249; Slomovitz et al., 2015), and tumors with TSC1/2 loss could also be targeted by mTOR inhibition (Bissler et al., 2013; Wagner et al., 2010).